The global gastrointestinal therapeutics market size is expected to reach USD 48.61 billion by 2030, advancing at a CAGR of 3.3% during the forecast period. Unhealthy eating habits, coupled with a sedentary lifestyle, have led to the development of gastrointestinal diseases among consumers, which is expected to drive market growth. Moreover, the rising adoption of biologics for the treatment of GI disorders is also fueling growth. For instance, REMICADE (Infliximab) by Janssen Biotech, Inc., and other biological drugs have been approved for the treatment of Crohn’s disease and ulcerative colitis.
The increasing incidences of industry-academia collaborations to promote gastrointestinal research and develop novel therapies for patients with GI disorders will likely facilitate market expansion. For instance, in November 2020, Takeda Pharmaceutical Company Limited, Columbia University, and New York University formed a collaborative research alliance to advance gastroenterology research programs, to develop new therapeutics for gastrointestinal diseases.
Moreover, market growth is also anticipated to increase research & development initiatives by government and private organizations for the development of new gastrointestinal drugs. As of November 2022, according to the U.S. National Library of Medicine, there were 7,586 ongoing clinical studies (including observational studies, drug development, and others) related to gastrointestinal diseases, at various stages of development. Moreover, in May 2022, AbbVie Inc. announced positive topline results from a phase-3 study that is evaluating upadacitinib in adult patients with severe to moderate Crohn's disease, who were intolerant to biologic therapy.
The presence of government and non-profit organizations that support gastrointestinal research, offer to fund studies, and promote awareness about GI disorders, is anticipated to augment GI therapeutics market growth. For instance, the International Foundation for Gastrointestinal Disorders, GI- research foundation, and American Gastroenterological Association are some of the key organizations supporting research activities and increasing awareness about gastrointestinal diseases among people. These organizations also raise funds for ongoing GI research activities.
Furthermore, various strategic initiatives such as product launches, collaboration, mergers, and acquisitions undertaken by leading players are expected to offer lucrative opportunities for market growth. For instance, in July 2022, Eli Lilly announced a partnership with the Chinese drug 3D printing firm to develop and research 3D-printed oral drugs for the GI tract application.
In addition, in April 2020acquired global rights, excluding Canada, Europe, and Israel, of Movantik (naloxegol) by AstraZeneca, for the management of opioid-induced constipation. This acquisition is expected to strengthen the company’s position in the global gastrointestinal therapeutics industry.
The increasing incidences of industry-academia collaborations to promote gastrointestinal research and develop novel therapies for patients with GI disorders will likely facilitate market expansion. For instance, in November 2020, Takeda Pharmaceutical Company Limited, Columbia University, and New York University formed a collaborative research alliance to advance gastroenterology research programs, to develop new therapeutics for gastrointestinal diseases.
Moreover, market growth is also anticipated to increase research & development initiatives by government and private organizations for the development of new gastrointestinal drugs. As of November 2022, according to the U.S. National Library of Medicine, there were 7,586 ongoing clinical studies (including observational studies, drug development, and others) related to gastrointestinal diseases, at various stages of development. Moreover, in May 2022, AbbVie Inc. announced positive topline results from a phase-3 study that is evaluating upadacitinib in adult patients with severe to moderate Crohn's disease, who were intolerant to biologic therapy.
The presence of government and non-profit organizations that support gastrointestinal research, offer to fund studies, and promote awareness about GI disorders, is anticipated to augment GI therapeutics market growth. For instance, the International Foundation for Gastrointestinal Disorders, GI- research foundation, and American Gastroenterological Association are some of the key organizations supporting research activities and increasing awareness about gastrointestinal diseases among people. These organizations also raise funds for ongoing GI research activities.
Furthermore, various strategic initiatives such as product launches, collaboration, mergers, and acquisitions undertaken by leading players are expected to offer lucrative opportunities for market growth. For instance, in July 2022, Eli Lilly announced a partnership with the Chinese drug 3D printing firm to develop and research 3D-printed oral drugs for the GI tract application.
In addition, in April 2020acquired global rights, excluding Canada, Europe, and Israel, of Movantik (naloxegol) by AstraZeneca, for the management of opioid-induced constipation. This acquisition is expected to strengthen the company’s position in the global gastrointestinal therapeutics industry.
Gastrointestinal Therapeutics Market Report Highlights
- Branded drugs held the largest share in the drug type segment in 2022, owing to high market penetration, ongoing product approvals, and extensive R&D efforts by pharma companies
- The generic drugs segment is expected to register the fastest growth rate through the forecast period, because of the rising patent expiration of branded drugs and the cost-effectiveness of generics
- In terms of drug class, the biologics/biosimilar segment accounted for the largest market share in 2022 due to extensive applications of biologics in severe GI diseases such as Crohn’s disease and ulcerative colitis
- Based on application, the Crohn’s disease segment dominated the GI therapeutics market in 2022, whereas the ulcerative colitis segment is anticipated to be the fastest-growing segment
- The retail pharmacy segment held the largest market revenue share in 2022, due to the easy accessibility to retail stores and the rising penetration of OTC drugs
- Asia Pacific is expected to exhibit the fastest growth during the forecast period due to the rising investments by market players and increasing disease prevalence in the region
Table of Contents
Chapter 1 Methodology and Scope1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Competitive Insights
Chapter 3 Gastrointestinal Therapeutics Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market
3.2 Market Dynamics
3.2.1 Market drivers analysis
3.2.1.1 Increase in development of biologics
3.2.1.2 High prevalence of gastrointestinal disorders
3.2.2 Market restraint analysis
3.2.2.1 High number of patent expirations
3.3 Penetration & Growth Prospect Mapping
3.4 Gastrointestinal Therapeutics: Market Analysis Tools
3.4.1 Industry analysis - Porter’s Five Forces
3.4.2 PESTLE analysis
3.5 Regulatory Framework
3.6 Pricing Analysis
Chapter 4 Gastrointestinal Therapeutics Market Segment Analysis, By Type, 2018 - 2030 (USD Million)
4.1 Definition and Scope
4.2 Type Market Share Analysis, 2022 & 2030
4.3 Segment Dashboard
4.4 Global Gastrointestinal Therapeutics Market, by Type, 2018 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.5.1 Branded
4.5.1.1 Branded market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients in Million)
4.5.2 Generic
4.5.2.1 Generic market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients in Million)
Chapter 5 Gastrointestinal Therapeutics Market Segment Analysis, By Drug Class 2018 - 2030 (USD Million)
5.1 Definition and Scope
5.2 Drug Class Market Share Analysis, 2022 & 2030
5.3 Segment Dashboard
5.4 Global Gastrointestinal Therapeutics Market, by Drug Class, 2018 to 2030
5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.5.1 Aminosalicylates
5.5.1.1 Aminosalicylates market estimates and forecast, 2018 - 2030 (USD Million)
5.5.2 Digestive enzymes
5.5.2.1 Digestive enzymes market estimates and forecast, 2018 - 2030 (USD Million)
5.5.3 Proton pump inhibitors
5.5.3.1 Proton pump inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
5.5.4 Laxatives
5.5.4.1 Laxatives market estimates and forecast, 2018 - 2030 (USD Million)
5.5.5 Anti-emetics
5.5.5.1 Anti-emetics market estimates and forecast, 2018 - 2030 (USD Million)
5.5.6 H2 antagonists
5.5.6.1 H2 antagonists market estimates and forecast, 2018 - 2030 (USD Million)
5.5.7 Anti-diarrheal
5.5.7.1 Anti-diarrheal market estimates and forecast, 2018 - 2030 (USD Million)
5.5.8 Biologics/Biosimilar
5.5.8.1 Biologics/Biosimilar market estimates and forecast, 2018 - 2030 (USD Million)
5.5.9 Others
5.5.9.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 6 Gastrointestinal Therapeutics Market Segment Analysis, By Route of Administration, 2018 - 2030 (USD Million)
6.1 Definition and Scope
6.2 Route of Administration Market Share Analysis, 2022 & 2030
6.3 Segment Dashboard
6.4 Global Gastrointestinal Therapeutics Market, by Route of Administration, 2018 to 2030
6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.5.1 Oral
6.5.1.1 Oral market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients in Million)
6.5.2 Injectable
6.5.2.1 Injectable market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients in Million)
6.5.3 Others
6.5.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 7 Gastrointestinal Therapeutics Market Segment Analysis, By Application, 2018 - 2030 (USD Million)
7.1 Definition and Scope
7.2 Application Market Share Analysis, 2022 & 2030
7.3 Segment Dashboard
7.4 Global Gastrointestinal Therapeutics Market, by Application, 2018 to 2030
7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
7.5.1 Crohn’s disease
7.5.1.1 Crohn’s disease market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
7.5.2 Ulcerative colitis
7.5.2.1 Ulcerative colitis market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
7.5.3 GERD
7.5.3.1 GERD market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
7.5.4 IBS
7.5.4.1 IBS market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
7.5.5 Others
7.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Chapter 8 Gastrointestinal Therapeutics Market Segment Analysis, By Distribution channel, 2018 - 2030 (USD Million)
8.1 Definition and Scope
8.2 Distribution Channel Market Share Analysis, 2022 & 2030
8.3 Segment Dashboard
8.4 Global Gastrointestinal Therapeutics Market, by Distribution Channel, 2018 to 2030
8.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
8.5.1 Hospital pharmacies
8.5.1.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
8.5.2 Retail pharmacies
8.5.2.1 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
8.5.3 Online pharmacies
8.5.3.1 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 9 Gastrointestinal Therapeutics Market Segment Analysis, By Region, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
9.1 Definition & Scope
9.2 Regional Market Share Analysis, 2022 & 2030
9.3 Regional Market Dashboard
9.4 Regional Market Snapshot
9.5 SWOT Analysis
9.5.1 North America
9.5.2 Europe
9.5.3 Asia Pacific
9.5.4 Latin America
9.5.5 Middle East and Africa
9.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030
9.6.1 North America
9.6.1.1 North America gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
9.6.1.2 U.S.
9.6.1.2.1 Key Country Dynamics
9.6.1.2.2 Competitive Scenario
9.6.1.2.3 Regulatory Framework
9.6.1.2.4 Reimbursement Scenario
9.6.1.2.5 U.S. market estimates and forecast, 2018 - 2030
9.6.1.3 Canada
9.6.1.3.1 Key Country Dynamics
9.6.1.3.2 Competitive Scenario
9.6.1.3.3 Regulatory Framework
9.6.1.3.4 Reimbursement Scenario
9.6.1.3.5 Canada market estimates and forecast, 2018 - 2030
9.6.2 Europe
9.6.2.1 Europe gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
9.6.2.2 UK
9.6.2.2.1 Key Country Dynamics
9.6.2.2.2 Competitive Scenario
9.6.2.2.3 Regulatory Framework
9.6.2.2.4 Reimbursement Scenario
9.6.2.2.5 UK market estimates and forecast, 2018 - 2030
9.6.2.3 Germany
9.6.2.3.1 Key Country Dynamics
9.6.2.3.2 Competitive Scenario
9.6.2.3.3 Regulatory Framework
9.6.2.3.4 Reimbursement Scenario
9.6.2.3.5 Germany market estimates and forecast, 2018 - 2030
9.6.2.4 Spain
9.6.2.4.1 Key Country Dynamics
9.6.2.4.2 Competitive Scenario
9.6.2.4.3 Regulatory Framework
9.6.2.4.4 Reimbursement Scenario
9.6.2.4.5 Spain market estimates and forecast, 2018 - 2030
9.6.2.5 France
9.6.2.5.1 Key Country Dynamics
9.6.2.5.2 Competitive Scenario
9.6.2.5.3 Regulatory Framework
9.6.2.5.4 Reimbursement Scenario
9.6.2.5.5 France market estimates and forecast, 2018 - 2030
9.6.2.6 Italy
9.6.2.6.1 Key Country Dynamics
9.6.2.6.2 Competitive Scenario
9.6.2.6.3 Regulatory Framework
9.6.2.6.4 Reimbursement Scenario
9.6.2.6.5 Italy market estimates and forecast, 2018 - 2030
9.6.2.7 Denmark
9.6.2.7.1 Key Country Dynamics
9.6.2.7.2 Competitive Scenario
9.6.2.7.3 Regulatory Framework
9.6.2.7.4 Reimbursement Scenario
9.6.2.7.5 Denmark market estimates and forecast, 2018 - 2030
9.6.2.8 Sweden
9.6.2.8.1 Key Country Dynamics
9.6.2.8.2 Competitive Scenario
9.6.2.8.3 Regulatory Framework
9.6.2.8.4 Reimbursement Scenario
9.6.2.8.5 Sweden market estimates and forecast, 2018 - 2030
9.6.2.9 Norway
9.6.2.9.1 Key Country Dynamics
9.6.2.9.2 Competitive Scenario
9.6.2.9.3 Regulatory Framework
9.6.2.9.4 Reimbursement Scenario
9.6.2.9.5 Norway market estimates and forecast, 2018 - 2030
9.6.3 Asia Pacific
9.6.3.1 Asia Pacific gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
9.6.3.2 Japan
9.6.3.2.1 Key Country Dynamics
9.6.3.2.2 Competitive Scenario
9.6.3.2.3 Regulatory Framework
9.6.3.2.4 Reimbursement Scenario
9.6.3.2.5 Japan market estimates and forecast, 2018 - 2030
9.6.3.3 China
9.6.3.3.1 Key Country Dynamics
9.6.3.3.2 Competitive Scenario
9.6.3.3.3 Regulatory Framework
9.6.3.3.4 Reimbursement Scenario
9.6.3.3.5 China market estimates and forecast, 2018 - 2030
9.6.3.4 India
9.6.3.4.1 Key Country Dynamics
9.6.3.4.2 Competitive Scenario
9.6.3.4.3 Regulatory Framework
9.6.3.4.4 Reimbursement Scenario
9.6.3.4.5 India market estimates and forecast, 2018 - 2030
9.6.3.5 South Korea
9.6.3.5.1 Key Country Dynamics
9.6.3.5.2 Competitive Scenario
9.6.3.5.3 Regulatory Framework
9.6.3.5.4 Reimbursement Scenario
9.6.3.5.5 South Korea market estimates and forecast, 2018 - 2030
9.6.3.6 Australia
9.6.3.6.1 Key Country Dynamics
9.6.3.6.2 Competitive Scenario
9.6.3.6.3 Regulatory Framework
9.6.3.6.4 Reimbursement Scenario
9.6.3.6.5 Australia market estimates and forecast, 2018 - 2030
9.6.3.7 Thailand
9.6.3.7.1 Key Country Dynamics
9.6.3.7.2 Competitive Scenario
9.6.3.7.3 Regulatory Framework
9.6.3.7.4 Reimbursement Scenario
9.6.3.7.5 Thailand market estimates and forecast, 2018 - 2030
9.6.4 Latin America
9.6.4.1 Latin America gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
9.6.4.2 Brazil
9.6.4.2.1 Key Country Dynamics
9.6.4.2.2 Competitive Scenario
9.6.4.2.3 Regulatory Framework
9.6.4.2.4 Reimbursement Scenario
9.6.4.2.5 Brazil market estimates and forecast, 2018 - 2030
9.6.4.3 Mexico
9.6.4.3.1 Key Country Dynamics
9.6.4.3.2 Competitive Scenario
9.6.4.3.3 Regulatory Framework
9.6.4.3.4 Reimbursement Scenario
9.6.4.3.5 Mexico market estimates and forecast, 2018 - 2030
9.6.4.4 Argentina
9.6.4.4.1 Key Country Dynamics
9.6.4.4.2 Competitive Scenario
9.6.4.4.3 Regulatory Framework
9.6.4.4.4 Reimbursement Scenario
9.6.4.4.5 Argentina market estimates and forecast, 2018 - 2030
9.6.5 MEA
9.6.5.1 MEA gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
9.6.5.2 South Africa
9.6.5.2.1 Key Country Dynamics
9.6.5.2.2 Competitive Scenario
9.6.5.2.3 Regulatory Framework
9.6.5.2.4 Reimbursement Scenario
9.6.5.2.5 South Africa market estimates and forecast, 2018 - 2030
9.6.5.3 Saudi Arabia
9.6.5.3.1 Key Country Dynamics
9.6.5.3.2 Competitive Scenario
9.6.5.3.3 Regulatory Framework
9.6.5.3.4 Reimbursement Scenario
9.6.5.3.5 Saudi Arabia market estimates and forecast, 2018 - 2030
9.6.5.4 UAE
9.6.5.4.1 Key Country Dynamics
9.6.5.4.2 Competitive Scenario
9.6.5.4.3 Regulatory Framework
9.6.5.4.4 Reimbursement Scenario
9.6.5.4.5 UAE market estimates and forecast, 2018 - 2030
9.6.5.5 Kuwait
9.6.5.5.1 Key Country Dynamics
9.6.5.5.2 Competitive Scenario
9.6.5.5.3 Regulatory Framework
9.6.5.5.4 Reimbursement Scenario
9.6.5.5.5 Kuwait market estimates and forecast, 2018 - 2030
Chapter 10 Gastrointestinal Therapeutics Market - Competitive Analysis
10.1 Recent Developments & Impact Analysis, by Key Market Participants
10.1.1 Ansoff matrix
10.1.2 Heat map analysis
10.1.3 Major Deals and Strategic Alliances Analysis
10.1.3.1 Joint Ventures
10.1.3.2 Licensing Agreements
10.1.3.3 Product Launches
10.1.3.1 Conferences and Campaigns
10.2 Company Categorization
10.2.1 Innovators
10.2.2 Market Leaders
10.3 Vendor Landscape
10.3.1 List of key distributors and channel partners
10.3.2 Key customers
10.4 Public Companies
10.4.1 Competitive Dashboard Analysis
10.4.1.1 Market Differentiators
10.5 Private Companies
10.5.1 List of key emerging companies
10.6 Company Profiles
10.6.1 AbbVie Inc
10.6.1.1 Company overview
10.6.1.2 Financial performance
10.6.1.3 Product benchmarking
10.6.1.4 Strategic Initiatives
10.6.2 AstraZeneca
10.6.2.1 Company overview
10.6.2.2 Financial performance
10.6.2.3 Product benchmarking
10.6.2.4 Strategic Initiatives
10.6.3 Takeda Pharmaceutical Company Limited
10.6.3.1 Company overview
10.6.3.2 Financial performance
10.6.3.3 Product benchmarking
10.6.3.4 Strategic Initiatives
10.6.4 Salix Pharmaceuticals
10.6.4.1 Company overview
10.6.4.2 Financial performance
10.6.4.3 Product benchmarking
10.6.4.4 Strategic Initiatives
10.6.5 Pfizer Inc
10.6.5.1 Company overview
10.6.5.2 Financial performance
10.6.5.3 Product benchmarking
10.6.5.4 Strategic Initiatives
10.6.6 Bayer AG
10.6.6.1 Company overview
10.6.6.2 Financial performance
10.6.6.3 Product benchmarking
10.6.6.4 Strategic Initiatives
10.6.7 Abbott
10.6.7.1 Company overview
10.6.7.2 Financial performance
10.6.7.3 Product benchmarking
10.6.7.4 Strategic initiatives
10.6.8 Janssen Global Services, LLC
10.6.8.1 Company overview
10.6.8.2 Financial performance
10.6.8.3 Product benchmarking
10.6.8.4 Strategic initiatives
10.6.9 Sun Pharmaceutical Industries Ltd
10.6.9.1 Company overview
10.6.9.2 Financial performance
10.6.9.3 Product benchmarking
10.6.9.4 Strategic initiatives
10.6.10 Cipla Inc
10.6.10.1 Company overview
10.6.10.2 Financial performance
10.6.10.3 Product benchmarking
10.6.10.4 Strategic initiatives
10.6.11 Gilead Sciences, Inc
10.6.11.1 Company overview
10.6.11.2 Financial performance
10.6.11.3 Product benchmarking
10.6.11.4 Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Leading Market Players Anticipated to Witness Highest Growth
Table 4 Global Gastrointestinal Therapeutics Market, By Region, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 5 Global Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 6 Global Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 7 Global Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 8 Global Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 9 Global Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 10 North America Gastrointestinal Therapeutics Market, By Country, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 11 North America Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 12 North America Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 13 North America Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 14 North America Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 15 North America Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 16 U.S. Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 17 U.S. Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 18 U.S. Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 19 U.S. Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 20 U.S. Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 21 Canada Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 22 Canada Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 23 Canada Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 24 Canada Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 25 Canada Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 26 Europe Gastrointestinal Therapeutics Market, By Country, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 27 Europe Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 28 Europe Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 29 Europe Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 30 Europe Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 31 Europe Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Germany Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 33 Germany Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 34 Germany Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 35 Germany Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 36 Germany Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 37 UK Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 38 UK Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 39 UK Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 40 UK Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 41 UK Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 42 France Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 43 France Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 44 France Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 45 France Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 46 France Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Italy Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 48 Italy Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 49 Italy Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 50 Italy Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 51 Italy Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 52 Spain Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 53 Spain Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 54 Spain Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 55 Spain Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 56 Spain Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 57 Denmark Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 58 Denmark Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 59 Denmark Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 60 Denmark Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 61 Denmark Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 62 Sweden Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 63 Sweden Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 64 Sweden Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 65 Sweden Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 66 Sweden Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Norway Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 68 Norway Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 69 Norway Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 70 Norway Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 71 Norway Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 72 Asia Pacific Gastrointestinal Therapeutics Market, By Country, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 73 Asia Pacific Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 74 Asia Pacific Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 75 Asia Pacific Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 76 Asia Pacific Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 77 Asia Pacific Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 78 Japan Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 79 Japan Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 80 Japan Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 81 Japan Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 82 Japan Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 83 China Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 84 China Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 85 China Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 86 China Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 87 China Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 88 India Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 89 India Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 90 India Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 91 India Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 92 India Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 93 South Korea Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 94 South Korea Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 95 South Korea Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 96 South Korea Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 97 South Korea Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 98 Australia Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 99 Australia Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 100 Australia Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 101 Australia Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 102 Australia Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 103 Thailand Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 104 Thailand Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 105 Thailand Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 106 Thailand Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 107 Thailand Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 108 Latin America Gastrointestinal Therapeutics Market, By Country, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 109 Latin America Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 110 Latin America Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 111 Latin America Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 112 Latin America Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 113 Latin America Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 114 Mexico Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 115 Mexico Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 116 Mexico Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 117 Mexico Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 118 Mexico Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 119 Brazil Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 120 Brazil Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 121 Brazil Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 122 Brazil Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 123 Brazil Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 124 Argentina Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 125 Argentina Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 126 Argentina Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 127 Argentina Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 128 Argentina Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 129 Middle East and Africa Gastrointestinal Therapeutics Market, By Country, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 130 Middle East and Africa Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 131 Middle East and Africa Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 132 Middle East and Africa Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 133 Middle East and Africa Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 134 Middle East and Africa Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 135 South Africa Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 136 South Africa Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 137 South Africa Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 138 South Africa Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 139 South Africa Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 140 Saudi Arabia Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 141 Saudi Arabia Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 142 Saudi Arabia Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 143 Saudi Arabia Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 144 Saudi Arabia Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 145 UAE Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 146 UAE Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 147 UAE Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 148 UAE Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 149 UAE Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 150 Kuwait Gastrointestinal Therapeutics Market, By Type, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 151 Kuwait Gastrointestinal Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
Table 152 Kuwait Gastrointestinal Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million) (Number of Patients in Million)
Table 153 Kuwait Gastrointestinal Therapeutics Market, By Application, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Table 154 Kuwait Gastrointestinal Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
FIG. 1 Gastrointestinal therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market outlook (2022)
Fig. 10 Strategy framework
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Penetration & growth prospect mapping
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Gastrointestinal therapeutics market: Type movement analysis
Fig. 17 Gastrointestinal therapeutics market: Type segment dashboard
Fig. 18 Gastrointestinal therapeutics market Type outlook: Key takeaways
Fig. 19 Branded market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients in Million)
Fig. 20 Generic market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients in Million)
Fig. 21 Gastrointestinal therapeutics market: Drug class movement analysis
Fig. 22 Gastrointestinal therapeutics market: Drug class segment dashboard
Fig. 23 Gastrointestinal therapeutics market Drug class outlook: Key takeaways
Fig. 24 Aminosalicylates market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Digestive enzymes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Proton pump inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Laxatives market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Anti-emetics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 H2 antagonists market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Anti-diarrheal market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Biologics/Biosimilar market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Gastrointestinal therapeutics market: Route of administration movement analysis
Fig. 34 Gastrointestinal therapeutics market: Route of administration segment dashboard
Fig. 35 Gastrointestinal therapeutics market Route of administration outlook: Key takeaways
Fig. 36 Oral market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients in Million)
Fig. 37 Injectable market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients in Million)
Fig. 38 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients in Million)
Fig. 39 Gastrointestinal therapeutics market: Application movement analysis
Fig. 40 Gastrointestinal therapeutics market: Application segment dashboard
Fig. 41 Gastrointestinal therapeutics market Application outlook: Key takeaways
Fig. 42 Crohn’s disease market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 43 Ulcerative colitis market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 44 GERD market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 45 IBS market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 46 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 47 Gastrointestinal therapeutics market: Distribution channel movement analysis
Fig. 48 Gastrointestinal therapeutics market: Distribution channel segment dashboard
Fig. 49 Gastrointestinal therapeutics market Distribution channel outlook: Key takeaways
Fig. 50 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Regional outlook, 2022 & 2030
Fig. 54 Regional market dashboard
Fig. 55 Regional market place: Key takeaways
Fig. 56 North America, SWOT
Fig. 57 Europe, SWOT
Fig. 58 Asia Pacific, SWOT
Fig. 59 Latin America, SWOT
Fig. 60 Middle East and Africa, SWOT
Fig. 61 North America
Fig. 62 North America gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 63 U.S.
Fig. 64 U.S. gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 65 Canada
Fig. 66 Canada gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 67 Europe
Fig. 68 Europe gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 69 U.K.
Fig. 70 U.K. gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 71 Germany
Fig. 72 Germany gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 73 Spain
Fig. 74 Spain gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 75 France
Fig. 76 France gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 77 Italy
Fig. 78 Italy gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 79 Sweden
Fig. 80 Sweden gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 81 Denmark
Fig. 82 Denmark gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 83 Norway
Fig. 84 Norway gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 85 Asia Pacific
Fig. 86 Asia Pacific gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 87 Japan
Fig. 88 Japan gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 89 China
Fig. 90 China gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 91 India
Fig. 92 India gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 93 South Korea
Fig. 94 South Korea gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 95 Australia
Fig. 96 Australia gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 97 Thailand
Fig. 98 Thailand gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 99 Latin America
Fig. 100 Latin America gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 101 Brazil
Fig. 102 Brazil gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 103 Mexico
Fig. 104 Mexico gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 105 Argentina
Fig. 106 Argentina gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 107 Middle East and Africa
Fig. 108 MEA gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 109 South Africa
Fig. 110 South Africa gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 111 Saudi Arabia
Fig. 112 Saudi Arabia gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 113 UAE
Fig. 114 UAE gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 115 Kuwait
Fig. 116 Kuwait gastrointestinal therapeutics market, 2018 - 2030 (USD Million) (Number of Patients by Type in Million)
Fig. 117 Ansoff Matrix
Fig. 118 Heat map analysis
Fig. 119 Market differentiators
Companies Mentioned
- AbbVie Inc
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- Salix Pharmaceuticals
- Pfizer Inc
- Bayer AG
- Abbott
- Janssen Global Services, LLC
- Sun Pharmaceutical Industries Ltd
- Cipla Inc
- Gilead Sciences, Inc
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | December 2022 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 39358.6 Million |
| Forecasted Market Value ( USD | $ 48610 Million |
| Compound Annual Growth Rate | 3.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
